

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
ATTY. DOCKET NO.

10997 U.S. PTO

10/068905



In re Patent Application of Simon Lemaire, et al.

Serial No.

Group Art Unit:

Filed:

Examiner:

For: Histogranin-Like Peptides And Non-Peptides, Processes For Their Preparation And Uses Thereof

**INFORMATION DISCLOSURE STATEMENT**

This Information Disclosure Statement is being filed in the manner prescribed by 37 CFR 1.97(b) - (d) to satisfy the duty under 37 CFR 1.56 to disclose to the Office information, known to individuals associated with the filing and prosecution of the subject application, which is material to the examination of the application.

In accordance with 37 CFR 1.97(g) and (h), this statement is not to be construed as a representation that a search has been made or an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 CFR 1.56(b).

In compliance with 37 CFR 1.98(a)(1), a list of all patents, publications or other information submitted for consideration by the Office is hereby provided by way of the attached Form PTO 1449.

In compliance with 37 CFR 1.98(a)(2), also enclosed is a legible copy of:

- i) each United States and foreign patent;
- ii) each publication or that portion which caused it to be listed; and

- iii) all other information or that portion which caused it to be listed, excluding any copies of a United States patent application.

It is respectfully requested that the information be expressly considered by the Examiner and that the references be made of record and appear among the "References Cited" on any patent to issue therefrom.

The Patent Office is hereby authorized to charge any deficiency, or credit any overpayment in fees to Deposit Account Number 23-0729

Respectfully submitted,

Dated: 2/07/02

Carol T. Spiller

Reg. No.

WELSH & KATZ  
120 South Riverside Plaza, 22<sup>nd</sup> Floor  
Chicago, Illinois 60606  
Telephone: (312) 655-1500

Encls.: Form PTO-1449  
All references listed on Form PTO-1449

<b>Form PTO-1449 (Modified)</b>  <b>LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)	<b>Atty. Docket No.</b>	<b>Serial No.</b>
	<b>Applicant</b> Simon Lemaire, et al.	
	<b>Filing Date</b>	<b>Group</b>

pc-997 U.S. PTO  
 10/068905  
 02707762

**REFERENCE DESIGNATION    U.S. PATENT DOCUMENTS**

EXAM. INIT.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FIL. DATE IF APPROPRIATE
AA	5 1 6 9 8 3 3	12/8/92	Hansen, Jr., et al.	514	17	
AB						

**FOREIGN PATENT DOCUMENTS**

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION
AC	2 2 1 9 4 3 7	4/24/99	Canada	C07K	5/103
AD					

**OTHER ART (including Author, Title, Date, Pertinent Pages, Etc.)**

AE	Lemaire, et al.	"Isolation and characterization of histogranin, a natural peptide with NMDA receptor antagonist activity." Eur. J. Pharmacol. - Molec. Pharmacol. Sec. (1993) 245:247-256.
AF	Boarder, et al.	"Met-enkephalin [Arg <sup>6</sup> ,Phe <sup>7</sup> ] immunoreactivity in bovine caudate and bovine adrenal medulla." J. Neurochem. (1982) 39(1):149-154.
AG	Liston, et al.	"Processing of proenkephalin is tissue-specific." Science. (August 17, 1984) 734-737.
AH	Lemaire, et al.	"Central and peripheral non-opioid analgesic activity of histogranin and related peptides." Soc. Neurosci. (1997) 23:674, abstract no. 267.13.
AI	Ruan, et al.	"Non-opioid antinociceptive effects of supraspinal histogranin and related peptides: possible involvement of central dopamine D <sub>2</sub> receptor." Pharmacol. Biochem Behav. (2000) 67:83-91.
AJ	Shukla, et al.	N-methyl-D-aspartate receptor antagonist activity and phencyclidine-like behavioral effects of the pentadecapeptide, [Ser <sup>1</sup> ]histogranin." Pharmacol. Biochem Behav. (1995) 50(1):49-54
AK	Siegan, et al.	"A natural peptide with NMDA inhibitory activity reduces tonic pain in the formalin model." NeuroReport. (1997) 8:1379-1381.
AL	Siegan, et al.	"Suppression of neuropathic pain by a naturally-derived peptide with NMDA antagonist activity." Brain Research. (1997) 755:331-334.
AM	Hama, et al.	"NMDA-induced spinal hypersensitivity is reduced by naturally derived peptide analog [Ser <sup>1</sup> ]histogranin." Pharmacol. Biochem. Behav. (1999) 62(1):67-74.
AN	Rogers, et al.	"Characterization of [ <sup>125</sup> I][Ser <sup>1</sup> ]histogranin binding sites in rat brain." J. Pharmacol. Exper. Ther. (1993) 267(1):350-356.
AO	Lemaire, et al.	"Characterization of histogranin receptors in human peripheral blood lymphocytes." Biochem. Biophys. Res. Comm. (1993) 194(3):1323-1329.
AP	Nishino, et al.	"Cyclo(-arginyl-sarcosyl-aspartyl-phenylglycyl-)2. Simple synthesis of an RGD-related peptide with inhibitory activity for platelet aggregation." J. Chem Soc., Perkin Trans. I. (1996) 939-946.
AQ	Osapay, et al.	"Synthesis of tyrocidine A: Use of oxime resin for peptide chain assembly and cyclization." Tetrahedron Letters. (1990) 31(43):6121-6124.
AR	Kaiser, et al.	"Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides." Anal. Biochem. (1970) 34:595-598.
AS	Matsueda, et al.	"A p-methylbenzhydrylamine resin for improved solid-phase synthesis of peptide amines." Peptides. (1981) 2:45-50.
AT	Lee, et al.	"Solid phase synthesis of 3,4-disubstituted-7-carbamoyl-1,2,3,4-tetrahydroquinoxalin-2-ones." J. Org. Chem. (1997) 62:3874-3879.
AU	Backes, et al.	"Activation method to prepare a highly reactive acylsulfonamide "safet-catch" linker for solid-phase synthesis." J. Am. Chem. Soc. (1996) 118:3055-3056.
AV	Lemaire, et al.	"Synthesis and biological activity of dynorphin-(1-13) and analogs substituted in positions 8 and 10." Int. J. Peptide Protein Res. (1986) 27:300-305.
AW	Shukla, et al.	"Selective involvement of kappa opioid and phencyclidine receptors in the analgesic motor effects of dynorphin-A-(1-13)-Tyr-Leu-Phe-Asn-Gly-Pro." Brain Research. (1992) 591:176-180.
AX	Hayashi, et al.	"The type of analgesic-receptor interaction involved in certain analgesic assays." Eur. J. Pharmacol. (1971) 16:63-66.
AY	D'Amour, et al.	"A method for determining loss of pain sensation." J. Pharmacol. Exp. Ther. (1941) 72:74-79.

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
-----------------	------------------------

EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>Form PTO-1449 (Modified)</b>  <b>LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)	Atty. Docket No.	Serial No.
	Applicant     Simon Lemaire, et al.	
	Filing Date	Group

**REFERENCE DESIGNATION    U.S. PATENT DOCUMENTS**

EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FIL. DATE IF APPROPRIATE
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
	BH							
	BI							
	BJ							
	BK							

**OTHER ART (including Author, Title, Date, Pertinent Pages, Etc.)**

	BL	Verma, et al.	"Role of D1/D2 dopamine and N-methyl-D-aspartate (NMDA) receptors in morphine tolerance and dependence in mice." Eur. Neuropsychopharmacol. (June, 1995) 5(2):81-87. Pub. Med. Abstract PMID 7549459
	BM	Sufka, et al.	"Stimulus properties and antinociceptive effects of selective bradykinin B <sub>1</sub> and B <sub>2</sub> receptor antagonists in rats." Pain. (1996) 66:99-103.
	BN	Lemaire, Irma	"Characterization of the bronchoalveolar cellular response in experimental asbestosis." Am. Rev. Respir. Dis. (1985) 131:144-149.
	BO		
	BP		
EXAMINER			
DATE CONSIDERED			

EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.